Clinical and pre-clinical immunotherapy research has mainly focused on checkpoint inhibitors in MCL [7], including PD-L1/PD-1 [8,9], TIM-3 [10] and TIGIT [11]. This evidence concerns the gene CD274 and mantle cell lymphoma.